Article Text
PDF
Abstract
Introduction/Background Our purpose is to evaluate the influence of the prognostic factors on the Disease-Free Survival (DFS) and Overall Survival (OS) in endometrial cancer (EC).
Methodology Retrospective review of 180 patients with EC. Standard surgical staging was performed with lymphadenectomy in 130 cases. Mean age was 63 years (27–94). Pathology most common was endometrioid adenocarcinoma (84.5%). Most frecuent FIGO stage was IA (47.8%). Mean follow-up was 46 months. The factors that impact on survival were compared using univariate and multivariate analysis.
Results The estimated 5-year DFS and OS comparated rates were respectively according to FIGO local stages (I) 93.9 and 90.2%, vs advanced stages (II–IV) 0 and 53.7% (p=0.00 Hazard ratio 5.58 (CI 95%, 2.74–11.35) and p=0.00 Hazard ratio 4.19 (CI 95%, 2.11–8.34), histological type I 92.3 and 89%, vs type II 28.1 and 58.3%% (p=0.00 Hazard ratio 2.91 (CI 95%, 1.3–6.57) and p=0, 01 Hazard ratio 2.6 (CI 95%, 1.17–5.77), histological low grade (G1) 89.1 and 92%, vs high grade (G2-3) 15.9 and 55.7% (p=0.00 Hazard ratio 5.79 (CI 95%, 2.42–13.85) and p=0.00 Hazard ratio 2.68 (CI 95%, 1.25–5.74); myometrial infiltration <50% 92.5 and 92.9%, vs >50% 63.9 and 66.1 (p=0.00 Hazard ratio 3.7 (CI 95%, 1.73–7.91) and p=0.00 Hazard ratio 4.31 (CI 95%, 1.92–9.7); in the abscence of lymphovascular space invasión (LVSI-) 94.4 and 89.7%, vs LVSI+ 0 and 62.6% (p=0.00 Hazard ratio 5.88 (CI 95%, 2.92–11.85) and p=0.01 Hazard ratio 2.4 (CI 95%, 1.17–4.89); lack of cervical stromal invasion 94.3 and 91.4%, vs present 26.6 and 87.8% (p=0.00 Hazard ratio 4.33 (CI 95%, 1.54–12.12) and p=0.63) and tumor size <2 cm 88.1 and 89.9%, vs tumor size >2 cm 64.9 and 78.2% (p=0.00 Hazard ratio 4.02 (CI 95%, 1.33–12.15) and p=0.12).
Conclusion The knowlegde of the histologic parameters is critical to the management of the EC.
Disclosure Nothing to disclose.
Disease-Free Survival (DFS) for lymphovascular space invasion (A) and Overall survival (OS) for hist
Overall survival (OS) for miometrial invasion (A). Disease-Free Survival (DFS) for cervical stromal